Ovarian Cancer

Patients with a positive AGO score had better survival outcomes with surgery plus chemotherapy, compared with chemotherapy alone.

The median PFS was 56.0 months with olaparib and 13.8 months with placebo.

Gemogenovatucel-T improved recurrence-free and overall survival at 3 years.

TP53 CHIP variants were significantly more common in patients with therapy-related myeloid neoplasms.

Patients treated at facilities with a high use of neoadjuvant chemotherapy had greater declines in 1-year mortality rates over time.

Avelumab did not improve progression-free survival when given concurrently with chemotherapy or as maintenance.

Most adverse events in the olaparib arm were manageable with supportive treatment or dose modifications.

PARP inhibitor use increased regardless of BRCA mutation status.

Individualized niraparib dosing should be considered standard practice, according to researchers.